Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 4/20 | 0.52 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.52 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.49 |
| ▸ | ABL1 | P00519 | 7/20 | 0.46 |
| ▸ | BCR | P11274 | 6/20 | 0.46 |
| ▸ | PRKCA | P17252 | 4/20 | 0.46 |
| ▸ | EGFR | P00533 | 4/20 | 0.46 |
| ▸ | SRC | P12931 | 3/20 | 0.46 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.46 |
| ▸ | PRKACA | P17612 | 1/20 | 0.46 |
| ▸ | PRKACG | P22612 | 1/20 | 0.46 |
| ▸ | PRKACB | P22694 | 1/20 | 0.46 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.46 |
| ▸ | SYK | P43405 | 1/20 | 0.46 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.46 |
| ▸ | AXL | P30530 | 1/20 | 0.45 |
| ▸ | CDK8 | P49336 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 2/20 | 0.44 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.44 |
| ▸ | PLK1 | P53350 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27115591 | 0.87 | CDK2 (0.55) | PIK3CGPIK3CAPIK3CBABL1BCR | |
| SCHEMBL3252954 | 0.86 | ABL1 (0.64) | PIK3CGPIK3CAPIK3CBABL1BCR | |
| SCHEMBL20998475 | 0.86 | PLK1 (0.57) | PIK3CGPIK3CAPIK3CBABL1BCR | |
| SCHEMBL3247346 | 0.84 | CLK1 (0.59) | CDK8KDRAURKA | |
| SCHEMBL13357453 | 0.79 | CDK1 (0.55) | PIK3CGPIK3CAPIK3CBPRKCAEGFR | |
| SCHEMBL27113508 | 0.75 | PIK3CG (0.55) | PIK3CGPIK3CAPIK3CBABL1BCR | |
| SCHEMBL14979755 | 0.74 | PDGFRA (0.59) | ABL1BCRPRKCAEGFRSRC | |
| SCHEMBL27115342 | 0.74 | JAK2 (0.57) | PIK3CGPIK3CAPIK3CBABL1BCR | |
| SCHEMBL6952728 | 0.72 | ZAP70 (0.65) | PIK3CGPIK3CAPIK3CBPRKCAEGFR | |
| SCHEMBL3249838 | 0.71 | CDK1 (0.76) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1896470-B1 | PYRROLOPYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2010-05-26 | — | — | EP | claimed |
| US-20080300267-A1 | Compounds and Compositions as Protein Kinase Inhibitors | TOYO BOSEKI KABUSHIKI KAISHA (JP) | 2008-12-04 | — | — | US | claimed |
| EP-1896470-A2 | PYRROLOPYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | IRM, LLC (BM) | 2008-03-12 | — | — | EP | claimed |
| WO-2006124863-A2 | PYRROLOPYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2006-11-23 | — | — | WO | claimed |
| EP-1896470-B1 | PYRROLOPYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2010-05-26 | — | — | EP | disclosed |
| EP-1896470-B1 | PYRROLOPYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2010-05-26 | — | — | EP | disclosed |
| US-20080300267-A1 | Compounds and Compositions as Protein Kinase Inhibitors | TOYO BOSEKI KABUSHIKI KAISHA (JP) | 2008-12-04 | — | — | US | disclosed |
| US-20080300267-A1 | Compounds and Compositions as Protein Kinase Inhibitors | TOYO BOSEKI KABUSHIKI KAISHA (JP) | 2008-12-04 | — | — | US | disclosed |
| US-20080300267-A1 | Compounds and Compositions as Protein Kinase Inhibitors | TOYO BOSEKI KABUSHIKI KAISHA (JP) | 2008-12-04 | — | — | US | disclosed |
| EP-1896470-A2 | PYRROLOPYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | IRM, LLC (BM) | 2008-03-12 | — | — | EP | disclosed |
| WO-2006124863-A2 | PYRROLOPYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300267-A1 | Compounds and Compositions as Protein Kinase Inhibitors | ERBB2, JAK2, AURKC | PIK3CG 89/4885PIK3CA 67/4885PIK3CB 61/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.